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Treatment strategies for patients with intermit-
tent claudication are primarily directed at sympto-
matic relief and improvement of the health-related
quality of life. Estimates of the expected benefit of
alternative strategies in terms of improved quality of
life are therefore essential for optimal decision mak-
ing both at the individual patient level and the
health policy level.
Traditionally, outcome studies in vascular medi-
cine have focused more on intermediary outcomes
such as graft patency. In the past few years, however,
the number of studies in vascular medicine that
report health-related quality of life has increased
considerably. With a few exceptions1-3 health-related
quality of life was assessed with health status mea-
sures. Health status measures are descriptive instru-
ments that categorize a person’s health on several
dimensions (e.g., mental health, pain, physical func-
tioning) but do not reflect the relative weight that
patients might give to the different dimensions.
Examples of general health status measures that have
been used in vascular medicine are the Nothingham
Health Profile,4,5 the Sickness Impact Profile,6 or the
SF36.7-9 The Walking Impairment Questionnaire is
an example of a disease-specific health status mea-
sure.10
The descriptive approach of these instruments
contrasts with that of preference-based methods,
which aim to assess the overall value or desirability
of a particular health state on a 0 to 1 or 0 to 100
scale.11,12 An important advantage of these health
value instruments is that they provide a metric that
can be used to calculate “quality adjusted life years”
in cost-effectiveness analyses, enabling comparison
of the relative efficiency of particular interventions
across different clinical fields.13,14
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An important concern with the use of such
instruments in a particular study population is their
validity, that is, whether the instruments measure
what they are supposed to measure. In the absence
of a true gold standard, one has to rely on indirect
approaches to assessing validity such as construct
validity. Assessment of the construct validity of an
instrument examines whether the instrument
behaves as it is expected to behave. A statistical asso-
ciation of disease severity with the scores on a par-
ticular instrument, with worse scores in patients with
more severe disease, would be considered indirect
evidence of the validity of that instrument. 
In this study we used several health value instru-
ments including the verbal rating scale,15 the time
trade-off, the standard gamble, the EuroQol,16 and
the Health Utilities Index, Mark III.17 All measures
are described in the Appendix. The purpose of our
study was (1) to elicit health values from patients
with intermittent claudication with these health
value instruments and (2) to study the construct
validity of the instruments by examining the relation
of the health values with symptom severity.
METHODS
Patients. We interviewed 92 patients with inter-
mittent claudication who participated in a 6-month
supervised exercise program of the vascular labora-
tory of the Department of Internal Medicine at our
hospital.18 All patients with intermittent claudica-
tion referred to Internal Medicine entered this exer-
cise program before alternative treatment strategies
were explored. Only patients with severe comorbid-
ity that would seriously interfere with reasonable
participation in the program (for example, severe
arthritis or severe congestive heart failure) were
excluded. Patients were instructed to walk just until
symptoms of claudication appeared and to repeat
this exercise several times a day. Participants
returned to the vascular laboratory every 2 months
for further instruction and assessment of their
hemodynamic and symptomatic status. After com-
pleting the program patients visited the laboratory
twice, at 12 and 36 months after the start of the
program, to evaluate long-term outcome. During
these follow-up visits the symptom-free walking dis-
tance and maximum walking distance were deter-
mined by having the patient walk back and forth
between two fixed points in the corridors of the
hospital. Each segment of this walk was performed
at the same speed. Patients were accompanied by
the vascular laboratory assistant, who ensured a
constant walking speed by monitoring the time
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needed to cover the distance between the two
points and requesting the patient to speed up or
slow down as necessary. The ankle/brachial index
and thigh/brachial index were measured at rest and
after exercise. If available for both limbs, we used
the lowest of the two values.
In mild cases of peripheral arterial occlusive dis-
ease, walking distance limited by pain is the central
phenomenon, and exercise programs are mainly
directed at increasing this distance. Therefore we
used the symptom-free walking distance as the pri-
mary measure of symptom severity in these patients.
Interviews. Patients were asked to complete a
questionnaire mailed to them 1 week before their
vascular laboratory visit. This part of the protocol
of our exercise program was implemented for the
purposes of our study, and patients started com-
pleting these questionnaires at different stages dur-
ing their follow-up. In this analysis we included
only the first available interview of each patient.
Approximately half of the patients (n = 45) had
already completed the exercise program at the time
of their first interview. 
The questionnaire included a set of disease-
specific questions, questions assessing the respon-
dents’ satisfaction with the exercise program, and a
Dutch translation of the RAND36, a health status
measure with nine dimensions that is nearly identical
to the SF36.19 To identify patients with additional
morbidity other than intermittent claudication, the
questionnaire included a list of 22 diseases (e.g.,
“diabetes”) and disease categories (e.g., “renal dis-
ease”). Overall comorbidity was defined as the pres-
ence of at least one specific form of comorbidity. Five
different health value instruments were included in
the questionnaire: the verbal rating scale, the time
trade-off, the standard gamble, the Health Utilities
Index, and the EuroQol, all described in more detail
in the Appendix. The first three instruments are
patient-based, that is, they ask patients to value their
own health status. The Health Utilities Index and the
EuroQol are examples of an alternative, population-
based approach, reflecting the preferences of the gen-
eral population rather than those of the individual
respondent. The Health Utilities Index and the
EuroQol include questions similar to those of the
descriptive health status measures, which categorize a
patient’s condition on several health dimensions.
Preference scores gathered previously from the gen-
eral population are then used to assign values to the
different health states that are defined by the scores
on the various dimensions. To enable comparison of
the average values from the various health value
Fig. 1. Verbal rating scale (VRS) values versus symptom-
free walking distance (SWD). Straight line, lowess curve
(see Methods); dotted line, logarithmic curve; dots, indi-
vidual values.
instruments, the EuroQol values and the average ver-
bal rating scale values were converted to time trade-
off and standard gamble values with a power trans-
formation proposed by Torrance20 (see Appendix).
Except for the standard gamble and the time
trade-off, the 30-page questionnaire was completed
at home during the week before the visit to the vas-
cular laboratory. The standard gamble and the time
trade-off were completed in a face-to-face interview
during the follow-up visit, and additional explana-
tion of the required task was provided when neces-
sary. The remainder of the questionnaire was also
checked for completeness. All interviews were per-
formed by the second author (W. D. K.), who was
specifically trained for this. On average, interviews
lasted approximately 30 minutes.
Data analysis. We examined the relation
between symptom-free walking distance and health
values both at a group level and at the individual
patient level. At the group level we compared aver-
age health values of patients with a symptom-free
walking distance ≤150 m with that of patients with a
symptom-free walking distance >150 m (150 being
the median value [rounded off] that we chose to
obtain groups of approximately equal size). The
Mann-Whitney U test was used to assess statistical
significance. At the individual patient level the statis-
tical association of symptom-free walking distance
with health values was assessed with the Spearman
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rank correlation. We also examined the functional
form of the relation between health values and
symptom-free walking distance by comparing vari-
ous parametric functions with a lowess-smoothed
curve that was fitted to the data. A lowess curve is a
locally weighted regression smoothing technique
that plots the central tendency of the outcome vari-
able as a function of the independent variable.
A problem with assessing the relation between
health values and symptom severity is that the esti-
mates that characterize this relation can be biased by
external factors such as comorbidity. It is possible,
for example, that patients with more severe symp-
toms have lower scores partly because they more fre-
quently have serious comorbidity. We examined the
effect of several such characteristics (age, sex, and
comorbidity) by entering them with the symptom-
free walking distance in a multiple linear regression
analysis with the health value measures as the depen-
dent variable.
RESULTS
The patient characteristics presented in Table I
are typical for patients with intermittent claudica-
tion, most being male and having an average age of
approximately 60 years. There is a high rate of self-
reported comorbidity (78%). Many patients report-
ed serious heart disease or history of myocardial
infarction (23%) or diabetes (29%).
Table II presents the average scores on the vari-
ous health value instruments of the patients at their
first interview. For all instruments the average value
was lower in patients with a symptom-free walking
distance ≤150 m compared with patients with a
symptom-free walking distance >150 m. Note that
for the time trade-off and the standard gamble,
Table I. Patient characteristics (n = 92)
Age (yr): mean, SD 60.5, 11.6
Sex: male/female 53/39
Duration of disease (mo): 29.5, 6, 13, 36
mean, p25, p50, p75
Bilateral symptoms (%) 49.3
Comorbidity (%) 78.3
Ankle/brachial index: mean, SD 0.79, 0.21
Ankle/brachial index, after exercise: 0.67, 0.23
mean, SD
Thigh/brachial index: mean, SD 0.84, 0.19
Thigh/brachial index, 0.76, 0.22
after exercise: mean, SD
Symptom-free walking distance: 273, 82, 128, 381
mean, p25, p50, p75 (m)
Maximum walking distance: 436, 157, 325, 688
mean, p25, p50, p75 (m)
p25, p50, p75, 25th, 50th, 75th percentile.
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however, the differences between the two groups are
small and not statistically significant. Only the verbal
rating scale and the EuroQol demonstrated a statis-
tically significant difference between the two groups.
For both groups the EuroQol-values were consider-
ably lower than those obtained with the other
instruments. After transformation, however, the
average values were quite similar to the time trade-
off and standard gamble values. In contrast, trans-
formation of the average verbal rating scale scores
yielded much higher values. As an illustration we
also included the average scores on two dimensions
of the RAND36: physical functioning and pain. As
with the health value instruments, lower scores were
found in patients with more severe symptoms.
Statistically significant differences were also found
for the RAND36 dimensions “physical role func-
tioning” (p = 0.026) and “general health percep-
tion” (p = 0.016).
At the individual patient level the statistical asso-
ciation of symptom-free walking distance with
health values varied from poor to moderate.
Spearman rank correlations, presented in Table III,
ranged from 0.03 (p = 0.78) for the time trade-off
to 0.34 (p = 0.003) for the verbal rating scale and
0.48 (p < 0.001) for the EuroQol. Similar estimates
were obtained for the maximum walking distance.
The ankle/brachial index and the thigh/brachial
index did not correlate at all with health values. The
correlation of the two RAND36 dimensions physical
functioning and pain with symptom-free walking
distance and maximum walking distance was fairly
good, and their correlation with health values was
similar to that found by others.1
The relation between symptom severity and
health values was examined further by plotting indi-
vidual patient health values against the symptom-
free walking distance and exploring possible func-
tional forms of the relation. Fig. 1 presents an exam-
ple, plotting verbal rating scale values as a function
of symptom-free walking distance. Clearly, there is
marked disparity in health values as obtained from
patients with the same or similar walking distances.
The lowess curve that was fitted to the data indicates
that there is a trend towards higher values as the
walking distance increases, but beyond approximate-
ly 300 m the curve levels off. Of the functional
forms examined, this pattern was best captured by a
logarithmic curve. For the other health value instru-
ments similar patterns were observed. Therefore a
log-transformation of the symptom-free walking dis-
tance was used in further analyses.
None of the health value measures correlated
significantly with age. On average, female patients
scored significantly lower on the EurQol (0.46 vs
0.52, p = 0.023). For the other health value mea-
sures differences between male and female patients
were not statistically significant. For all health value
measures the average values were lower in patients
with comorbidity, but the differences were small
Table II. Health values of patients with a symptom-free walking distance ≤150 m versus >150m
SWD ≤150 m SWD > 150 m p Value 
(59%) (41%) (two-sided)
Patient-based values
Verbal rating scale 0.71 (0.13) 0.80 (0.13) 0.005
Time trade-off 0.75 (0.25) 0.78 (0.22) 0.667
Standard gamble 0.86 (0.22) 0.87 (0.19) 0.944
Population-based values
EuroQol 0.45 (0.12) 0.61 (0.18) <0.001
Health Utilities Index 0.73 (0.19) 0.81 (0.09) 0.146
Transformed values*
Verbal rating scale (TTO) 0.86 0.93
Verbal rating scale (SG) 0.93 0.97
EuroQol (TTO) 0.71 (0.12) 0.83 (0.13) <0.001
EuroQol (SG) 0.83 (0.09) 0.92 (0.09) <0.001
RAND36 dimensions†
Pain 44 (16) 63 (26) <0.001
Physical functioning 56 (21) 76 (20) <0.001
SWD, Symptom-free walking distance; TTO, time trade-off; SG, standard gamble.
*A power function was used to transform verbal rating scale and EuroQol values to time trade-off and standard gamble scores. For the
verbal rating scale, the transformed values are based on the sample average; therefore no standard deviations or p values are listed (see
Appendix).
Of the other RAND36 dimensions, also “physical role functioning” and “general health perception” demonstrated statistically signifi-
cant differences between the two groups.
Data are expressed as mean (standard deviation).
JOURNAL OF VASCULAR SURGERY
426 de Vries, Kuipers, and Hunink March 1998
(ranging from -0.01 to -0.05) and not statistically
significant. For some specific forms of comorbidity,
however, differences were larger and statistically sig-
nificant. Patients who reported severe chronic (i.e.,
>3 months) intestinal problems (n = 6), for example,
scored considerably lower on the verbal rating scale
(-0.22, p < 0.001) and the Health Utilities Index 
(-0.22, p = 0.018). Patients who reported arthritis
(n = 12) scored lower on the verbal rating scale 
(-0.07, p = 0.045), the standard gamble (-0.10, p =
0.045), the EuroQol (-0.12, p = 0.012), and the
Health Utilities Index (-0.17, p = 0.003). Generally,
comorbidity did not correlate with the symptom-
free walking distance. 
The influence of the covariates age, sex, and
comorbidity was further examined in a multiple lin-
ear regression analysis with health value as the
dependent variable and the log-transformed symp-
tom-free walking distance as an explanatory variable.
None of the three covariates influenced the size of
the effect of symptom-free walking distance on the
health values. The use of specific forms of comor-
bidity instead of overall comorbidity yielded similar
results. This result indicates that our estimates of the
correlation between symptom-free walking distance
and health values were not seriously biased by dif-
ferences among the respondents in age, sex, or
comorbidity.
DISCUSSION
In this study we obtained health values from
patients with intermittent claudication with five dif-
ferent instruments, and we compared these values
with the symptom-free walking distance as a mea-
sure of symptom severity. The average health values
were lower in patients with more severe symptoms,
and differences were statistically significant for the
verbal rating scale and the EuroQol, which can be
considered indirect evidence of the validity of these
instruments in this patient population.
The use of health-related quality of life instru-
ments in vascular medicine as a supplement to more
traditional outcome measures has increased consid-
erably over the past few years, but only a few stud-
ies have included health value instruments.1-3 An
advantage of health value instruments is that the
results can be used to calculate “quality adjusted life
years” in cost-effectiveness analyses. At various lev-
els of decision making health value measurement
may provide valuable information, supplementing
that of the more traditional outcome measures in
vascular medicine. However useful health value
instruments are in optimizing clinical and health
policy decision making, the validity of the instru-
ments in patients with peripheral arterial occlusive
disease is an important issue that must be addressed.
In the absence of a true gold standard, our approach
to assessing validity is an indirect one, relating
symptom severity to health values as obtained with
the different instruments. Whereas several authors
have looked at the association of health values with
health status measures 1,15, 21-23 or the association of
health status measures with symptom severity,6-8
our study directly relates health values to a clinical
measure of symptom severity.
A possible limitation of our study is the fact that
the symptom-free walking distance is subject to con-
siderable intrapatient, that is, day-to-day variability.
With health value measurement, on the other hand,
respondents probably value their health status as
perceived over a longer period of time. In most
instruments they are even asked specifically to do so.
The variability of the symptom-free walking distance
will tend to dilute the statistical association with
Table III. Spearman rank correlations
ABI TBI SWD MWD VRS TTO SG EuroQol HUI PF
TBI 0.79 -
SWD 0.25 0.18 -
MWD 0.36 0.23 0.84 -
VRS -0.03 -0.17 0.34 0.35 -
TTO -0.05 -0.11 0.03 0.00 0.18 -
SG -0.17 -0.26 0.10 -0.01 0.30 0.55 -
EuroQol 0.11 0.02 0.48 0.36 0.54 0.11 0.16 -
HUI -0.01 0.10 0.13 0.11 0.38 0.13 0.19 0.54 -
PF 0.03 -0.07 0.47 0.49 0.36 0.20 0.32 0.37 0.28 -
Pain -0.06 -0.03 0.51 0.43 0.44 0.11 0.20 0.55 0.48 0.37
ABI, Ankle/brachial index; TBI, thigh/brachial index; SWD, symptom-free walking distance; MWD, maximum walking distance; VRS,
verbal rating scale; TTO, time trade-off; SG, standard gamble; HUI, Health Utilities Index; PF, RAND 36 dimension “Physical func-
tioning”; Pain, RAND 36 dimension “Pain.”
health values. An alternative approach would be to
measure symptom-free walking distance on several
consecutive days and to use the average value as an
indicator of symptom severity, but this would have
been highly impractical in a clinical setting. Part of
the questionnaire was not completed on the same
day as the walking test. The difference in time
between the measurements was relatively small (≤7
days), however, and test-retest reliability studies
indicate that health values are stable over time, even
with longer time periods.24-26
The cutoff value that we used (150 m) to define
our two groups was in essence an arbitrary one. We
picked the median value (rounded off) to obtain
groups of approximately equal size. In secondary
analyses we looked at the influence of the use of
alternative cutoff values (100, 200, 250, and 300 m,
respectively) and found similar results; averages were
lower in patients with more severe disease, and dif-
ferences were statistically significant only for the
EuroQol and the verbal rating scale.
Our study population consisted of patients with
intermittent claudication who participated in an
exercise program. Although the inclusion criteria for
the program were very liberal, the study population
may not be completely representative of all patients
with intermittent claudication, because patients with
severe comorbidity that would interfere with reason-
able participation in the program were excluded.
Another implication is that our study was not able to
examine the effects of these severe forms of comor-
bidity on health values. It might be expected that
the perceived health-related quality of life in this par-
ticular subgroup of patients with intermittent clau-
dication is dominated by symptoms other than clau-
dication, and current health value measures are
probably not sensitive enough to detect additional
effects of the severity of the claudication.
The order of the health value measures was fixed:
first the Health Utilities Index, then the verbal rat-
ing scale, EuroQol, time trade-off, and standard
gamble. It has been suggested that when multiple
health value measures are used, respondents tend to
use the standard gamble score as an anchor.27
Therefore we placed the standard gamble last.
Theoretically, it is nevertheless possible that other
order effects affected the scores on the instruments
at the end of the series, and if so, this may also have
interfered with independent assessment of their con-
struct validity. Random assignment of the order of
the instruments would have enabled further exami-
nation of possible order effects, but for logistic rea-
sons such a design was not feasible in our study.
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The ability of a health value instrument to dis-
criminate among groups of patients with different
symptom severity is an indication of its validity and
supports its use in assisting decision making at the
more aggregated level, for example, in health policy
or in the construction of protocols. Here, mean val-
ues are required to estimate the benefits of alterna-
tive strategies in a particular patient group.
Depending on the perspective of the analysis, either
population-based or patient-based instruments are
more relevant. If, for example, the analysis takes a
societal perspective, both the Health Utilities Index
and the EuroQol would provide valuable alterna-
tives. Both are relatively easy to understand by the
respondents, take little time to complete, and after
transformation of the EuroQol values, yield values
that are at least in the same order of magnitude.
Both measures yielded lower average values in
patients with more severe disease, but the difference
was statistically significant only for the EuroQol. If a
patient perspective is required, the time trade-off,
the standard gamble, or the verbal rating scale
would be more relevant. The time trade-off and
standard gamble have a more thorough theoretical
underpinning than the verbal rating scale, but they
are also more time-consuming and cognitively
demanding, and we found relatively poor discrimi-
natory properties for these two instruments in our
patient population. Whereas all three patient-based
instruments yielded lower average values in patients
with more severe symptoms, the difference was sta-
tistically significant only for the verbal rating scale.
At the individual patient level the Health
Utilities Index and EuroQol are probably less rele-
vant because of their population perspective.
Possible applications of health value instruments at
this level include monitoring of treatment effects
and, in the future, use in patient-based decision
models to assist clinical decision making. We
observed considerable variability of the health values
in patients with very similar walking distances (Fig.
1). A possible source of heterogeneity, especially for
the time trade-off and the standard gamble, is
“noise” introduced by poor understanding of the
required task, which would seriously limit their
applicability at this level. Furthermore the range of
health values is relatively limited; in particular, the
time trade-off and the standard gamble tend to clus-
ter close to 1. This reduces the statistical power to
detect an effect of symptom severity on these health
values. Another important possible explanation for
the poor correlations are differences among subjects
in the weights they give to the various aspects of
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health, differences in their “health demands” in gen-
eral, and differences in their risk attitude. An active
patient with a particular symptom-free walking dis-
tance may feel much more limited by the symptoms
of intermittent claudication than a patient who has
the same symptom-free walking distance but leads a
more sedentary life. Health outcomes may be
assessed at many different levels (e.g., biologic/phys-
iological, symptomatic, functional, or health value
level), and each of these levels may be the most rele-
vant one from a particular perspective. Individual
health preferences influence how, for example, health
outcomes at the symptomatic and functional level
map to health values. Because these preferences may
differ from patient to patient, it is probably not real-
istic to expect more than moderate correlations
between health outcomes at different levels. Thus
poor correlations between measures of symptom
severity and health values do not prove that the health
value measures do not correctly reflect a patient’s val-
uation of his or her health status. Provided that indi-
vidual health preferences remain constant over time,
different health preferences would play a less promi-
nent role as a source of heterogeneity in a longitudi-
nal study that would relate changes in symptom
severity to changes in health values. Such a follow-up
study could therefore provide valuable additional
information as to the validity of the health value mea-
sures. Unfortunately, at the time of this study follow-
up interviews were available for only 25 patients,
which precluded any meaningful inference from such
an analysis. Continuing data collection at our institu-
tion will enable such a longitudinal approach in the
near future.
We conclude that at least for the verbal rating
scale and the EuroQol, the results of our study pro-
vide indirect evidence of the validity of health value
measures in a population of patients with peripheral
arterial occlusive disease.
We thank Johanna Bosch, MSc, for her expert advise
on choosing and implementing the health-related quality
of life instruments in our study.
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APPENDIX
Health value instruments. Five different health
value measures were used: the verbal rating scale, the
time trade-off, the standard gamble, the Health
Utilities Index, and the EuroQol. The first three
measures are patient-based; they ask patients to value
their own state of health. The Health Utilities Index
and the EuroQol are population-based, reflecting
values from the general population. The key elements
of the various instruments are presented.
Verbal rating scale. With the verbal rating scale
respondents were asked to specify a number between
0 and 100 that represents the desirability of their
health status compared with death (0) and perfect
health (100).15 The exact wording of the question
was (translated from Dutch): “If you had to rate your
general state of health during the past 4 weeks on a
scale from 0 to 100 points, where 100 is full health
and 0 is death, how many points would you give?”1
Time trade-off. With the time trade-off respon-
dents were asked to imagine that they would live
another fixed number of years in their current state
of health (defined as the average of the past 4
weeks). The number of years varied with the age of
the respondent: 30, 20, and 10 years for the age
groups 54 years old or younger, 55 to 64 years, and
tionnaire is available from the EuroQol Group (Dr.
F.Th. de Charro, Center for Health Policy and Law,
Faculty of Law, Erasmus University, Rotterdam, the
Netherlands).
Transformation. To enable comparison of the
average values from the various health value instru-
ments, a power transformation proposed by
Torrance20 was used that converts average visual
analog scale or verbal rating scale values to time
trade-off and standard gamble values: U = 1 - (1 -
V)b , where U is the time trade-off or standard gam-
ble value, and V is the average visual analog scale or
verbal rating scale value. Different values for b have
been proposed. For the transformation of the aver-
age verbal rating scale value to a time trade-off and
standard gamble value, we used a b of 1.61 and
2.19, respectively, based on empiric work by
Torrance et al.20,30 Individual EuroQol scores
reflect the average visual analog scale value from the
general population for a particular health profile (see
previous description). The estimates of b we used to
convert the EuroQol-values to time trade-off and
standard gamble values were based on Busschbach et
al.29 (b = 2.16 and 3.22, respectively). The b esti-
mates from the Torrance and Busschbach studies
differ probably because of the different descriptions
used for the lower end of the scale.
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ues can be assigned to each of the health profiles.28
These values are based on standard gamble and visu-
al analog scale scores transformed to standard gamble
scores for a subset of all possible health profiles. The
values were determined among a random sample of
the general population (Hamilton, Canada).17 The
questionnaire is available from the Health Utilities
Index Group (Dr. D. Feeny or Dr. W. Furlong,
Center for Health Economics and Policy Analysis,
McMaster University, Toronto, Canada).
EuroQol. The EuroQol has five different health
dimensions: mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression.16 There are
three alternative answers per dimension, allowing for
243 different combinations. Values are based on non-
transformed visual analog scale scores (the “EuroQol
thermometer”) that were obtained from the general
population (Rotterdam, the Netherlands).29 The
“EuroQol thermometer” differs from the visual ana-
log scale used for the Health Utilities Index; the
description of the lower end of the scale is “worst
imaginable health state” instead of “death.” Several
possible models are provided that assign values to the
health profiles.29 In this study we used the model that
is based on the means of the original visual analog
scale scores and which allows separate modeling of the
middle response level of each dimension. The ques-
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